Supplemental material for: Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database

Pierre-Antoine Juge, Lidwine Wémeau-Stervinou, Sébastien Ottaviani, Guillaume Desjeux, Joe Zhuo, Virginie Vannier-Moreau, Rene-Marc Flipo, Bruno Crestani, Philippe Dieudé

Supplemental Table 1  Overall prevalence and incidence rates of RA-ILD in France

<table>
<thead>
<tr>
<th></th>
<th>Prevalence* per 100,000 inhabitants</th>
<th>Incidence† per 100,000 person-years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>6.5</td>
<td>1.0</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>5.4</td>
<td>0.9</td>
</tr>
<tr>
<td>Female</td>
<td>7.6</td>
<td>1.2</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>1.7</td>
<td>0.2</td>
</tr>
<tr>
<td>65–74</td>
<td>12.8</td>
<td>1.7</td>
</tr>
<tr>
<td>≥75</td>
<td>14.8</td>
<td>2.1</td>
</tr>
</tbody>
</table>

†Incidence calculated from 2014–2018.

RA, rheumatoid arthritis; ILD, interstitial lung disease; RA-ILD, RA with ILD.
Supplemental Figure 1 Survival in patients with RA-ILD versus RA-noILD in the matched population: sensitivity analyses after matching for cardiometabolic comorbidities.

**Arterial disease**
- RA-noILD (n=1880)
- RA-ILD (n=1893)

**Cardiac disease**
- RA-noILD (n=1449)
- RA-ILD (n=1449)

**Diabetes**
- RA-noILD (n=1122)
- RA-ILD (n=1122)

**Dyslipidaemia**
- RA-noILD (n=2178)
- RA-ILD (n=2178)

HR 2.6, 95% CI 2.3 to 3.0, p<0.001
HR 3.3, 95% CI 2.9 to 3.7, p<0.001
HR 3.1, 95% CI 2.8 to 3.6, p<0.001
HR 3.0, 95% CI 2.6 to 3.5, p<0.001
p-values determined by log rank test.
ILD, interstitial lung disease; RA, rheumatoid arthritis; RA-ILD, RA with ILD; RA-noILD, RA without ILD.